The Wolverine Stack: What It Is and Where the Name Came From

The "Wolverine stack" is BPC-157 and TB-500 taken together. The name comes from the comic character whose defining trait is rapid healing, and it was coined by the community rather than by anyone studying either compound.

That origin is worth stating plainly, because the name does a lot of persuasive work that the evidence does not.

What each contributes

The pairing rationale is that the two act through different proposed pathways toward similar proposed outcomes. See the BPC-157 dosage guide and the TB-500 guide for what each literature does and does not establish.

What the research actually shows

The two compounds are at different points on the evidence scale, and neither is where the name implies.

BPC-157 is derived from a sequence identified in gastric juice. Its literature is substantial in volume — gut, tendon, ligament, muscle and nerve injury models — with angiogenesis and growth-factor receptor expression proposed as the mechanism (Sikiric 2011). One frequently cited rat study reported accelerated tendon outgrowth and cell migration after Achilles injury (Chang 2011). Two qualifiers matter more than the volume: almost all of it is rodent work, and a large share originates from a single research group, so independent replication is thinner than the citation count suggests. There is no completed controlled human efficacy trial for any indication.

TB-500 requires a distinction vendors routinely blur. Thymosin beta-4 is a naturally occurring actin-sequestering protein with a genuine role in cell migration and wound repair (Goldstein 2005). The parent protein reached human trials: a randomised placebo-controlled phase 2 study in dry eye, and a European randomised study in venous ulcers (Sosne and Ousler 2015; Guarnera 2007). Results were modest rather than decisive. Those trials tested thymosin beta-4 itself — not the TB-500 fragment sold for research, and not by the route this combination uses.

Recent structured reviews of injectable peptides in sports medicine reach the same conclusion from the clinical side: the evidence base does not support the claims made for these compounds in athletic recovery, and the gap between marketing and data is the defining feature of the category (Villegas Meza 2026; Tewari 2026).

What the evidence does not show

• Nothing about the combination. No study, controlled or otherwise, has tested BPC-157 and TB-500 together in humans or animals.

• No human efficacy for BPC-157 at all, by any route, for any indication.

• Nothing that transfers from the parent protein to the fragment. Thymosin beta-4's trial results are not TB-500's results.

• No established dose. The figures circulating come from community practice and vendor labelling, not human pharmacokinetics.

Combinations discussed alongside this one, each with an explicit evidence grade, are catalogued in the peptide stacks directory.

The composition is not fixed

"Wolverine stack" is a nickname, not a formulation, and it does not always mean the same two compounds.

The two-component version — BPC-157 plus TB-500 — is what most vendors, forums and articles mean. But some clinics market a four-component protocol under the same name, adding CJC-1295 and ipamorelin on the reasoning that a raised growth-hormone background supports tissue repair. That is a materially different proposition with a different risk profile, sold under an identical label.

Two adjacent blends complicate the naming further, since both contain the same pair plus more:

The practical consequence is that the name tells you almost nothing about what is in a vial. Check the per-component masses on the label rather than trusting the term.

Where the name causes problems

A name like "Wolverine stack" sets an expectation before any evidence is examined. It is the same pattern as DSIP being named "sleep-inducing peptide" and MOTS-c being called an "exercise mimetic" — the label asserts a conclusion the research has not reached.

The underlying compounds are genuinely interesting. The framing that they confer a healing factor is marketing.

What before-and-after reports can and cannot tell you

Personal accounts are the most abundant evidence on this combination and the least informative, for reasons worth naming rather than dismissing.

• Injuries improve on their own. Most soft-tissue injuries recover over weeks to months regardless of intervention. An account that ends "and six weeks later it was better" describes the natural history as readily as an effect.

• People start when symptoms are worst. Beginning at peak pain means the expected direction of travel is improvement whatever happens next — the reason controlled trials exist.

• The combination cannot be attributed. With two compounds, plus whatever rehab, rest and load management ran alongside, no single factor can be isolated.

• Reports are filtered before they are posted. People who improve write it up; people who did not, or who stopped early, mostly do not. What surfaces is not a representative sample.

None of that makes individual accounts dishonest. It makes them unable to answer the question they are being used to answer.

Reported effects, safety and anti-doping status

Neither compound has been through the safety evaluation an approved drug receives, so there is no adverse-event profile in the sense a medicine has one. Rodent toxicology exists for BPC-157; human tolerability data exists only for thymosin beta-4 rather than the TB-500 fragment, where it was reported as generally well tolerated in the trials above.

What research communities describe most often is local: injection-site reactions, transient soreness, occasional lightheadedness. Those reports are uncontrolled and subject to the filtering described above.

The clearest documented risk is not physiological. Both compounds are prohibited under the World Anti-Doping Code, BPC-157 and TB-500 alike, in and out of competition. For any tested athlete this is the decisive fact about the combination, and recent sports-medicine reviews single out exactly this gap between how the compounds are marketed and their anti-doping status (Villegas Meza 2026).

Purity is a separate concern. These are sold as research chemicals with no pharmaceutical manufacturing oversight, so what a vial contains is established by a certificate of analysis or not at all — the guide to reading a COA covers what to check.

The vial math

Sold either as two separate vials or pre-blended. The blend introduces the labelling ambiguity that catches most people: does a stated total mean the sum, or the amount of each?

Separate vials, reconstituted independently

Note the scale difference. BPC-157 is discussed in micrograms and TB-500 in milligrams, which is exactly why a fixed-ratio blend is awkward for this pair — one draw cannot suit both.

The BPC-157 and TB-500 guide works through blend arithmetic in detail, and the peptide calculator handles per-component concentrations.

Storage

Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.

Frequently asked questions

What is the Wolverine peptide stack?

A community nickname for BPC-157 combined with TB-500, named after the comic character's healing factor. It is not a product, not a formulation, and not a protocol from any clinical source. Some clinics use the same name for a four-component version that adds CJC-1295 and ipamorelin.

What peptides are in the Wolverine stack?

Most commonly two: BPC-157 and TB-500. Because the name is informal, check the per-component masses on any vial rather than relying on the label.

Does the Wolverine stack actually work?

No controlled human trial has tested it, so there is no evidence-based answer. Both components have preclinical literature, neither has completed a human efficacy trial, and the combination has never been studied at all.

Is the Wolverine stack safe?

There is no adequate safety data. Neither compound has completed the evaluation an approved drug undergoes, and the reports that exist are uncontrolled. Both are prohibited in tested sport, which is a documented consequence rather than a theoretical one.

Is the Wolverine stack a product?

It is a community name for a combination, not a branded product. Vendors sell the components, sometimes pre-blended.

Is a blend better than separate vials?

A blend is cheaper and simpler, but fixes the ratio and makes it impossible to attribute any effect to one component. Separate vials cost more and preserve both. The scale mismatch between the two compounds makes this trade-off sharper here than for most pairs.

How does it relate to GLOW and KLOW?

Both of those blends contain BPC-157 and TB-500 plus additional components. See GLOW and KLOW.